Inhaled Levodopa Improves Motor Symptoms in Parkinson's Inhaled Levodopa Improves Motor Symptoms in Parkinson's
Phase 3 study results showed that inhaled formulation of levodopa outperformed placebo at 12 weeks, reducing ' off ' periods and improving motor scores in patients with Parkinson ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Inhaled Levodopa Cuts Motor Symptoms in Parkinson's'Off' Episodes
(MedPage Today) -- Drugmaker Acorda to seek FDA approval shortly (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 8, 2017 Category: Primary Care Source Type: news
Novel Parkinson Therapies Highlighted at AAN Meeting
(MedPage Today) -- Early results with gene therapy, new carbidopa-levodopa formulation featured (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 27, 2017 Category: Geriatrics Source Type: news
150-Year-Old Drug May Help Parkinson's Patients
Study finds apomorphine cuts the time until levodopa kicks in for those with advanced disease (Source: WebMD Health)
Source: WebMD Health - April 22, 2017 Category: Consumer Health News Source Type: news
Acorda plans NDA for inhaled Parkinson ’ s drug after touting long-term safety data
Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group.
The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Ardsley, N.Y.-based company said the 12-month safety results are consistent with data from Phase IIb and III clinical evaluations.
Get the full story at our sister...
Source: Mass Device - March 30, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Respiratory Wall Street Beat Acorda Therapeutics Source Type: news
New Parkinson's Drug Xadago Approved
WEDNESDAY, March 22, 2017 -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson ' s patients who take levodopa or carbidopa but have instances of increased symptoms anyway, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news
FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - March 22, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news
FDA OKs Parkinson's Add-On Drug, Xadago (Safinamide)
WEDNESDAY, March 22, 2017 -- The U.S. Food and Drug Administration has approved a new drug for Parkinson ' s disease.
Xadago (safinamide) pills were given the green light as an add-on treatment for people taking levodopa/carbidopa and experiencing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news
FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson's symptoms, such as tremor and difficulty walking. (Source: World Pharma News)
Source: World Pharma News - March 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Okays Safinamide (Xadago) for Parkinson's Disease FDA Okays Safinamide (Xadago) for Parkinson's Disease
Safinamide is approved as adjunctive treatment for patients with Parkinson ' s disease who experience ' off ' episodes while taking levodopa/carbidopa.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Troubled MAOI for PD'Off' Episodes Nabs FDA Approval
(MedPage Today) -- Safinamide had rocky regulatory road as levodopa/carbidopa add-on (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 21, 2017 Category: Geriatrics Source Type: news
FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson ’s Disease
March 21, 2017 -- The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2017 Category: Drugs & Pharmacology Source Type: news
FDA approves Newron's drug as add-on therapy for Parkinson's
(Reuters) - Newron Pharmaceuticals SpA said on Tuesday the U.S. Food and Drug Administration approved its Parkinson's disease treatment Xadago as an add-on therapy to levodopa, a drug widely used to treat the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves drug to treat Parkinson ’ s disease
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’ s disease who are currently taking levodopa/carbidopa and experiencing “ off ” episodes. An “ off ” episode is a time when a patient ’ s medications are not working well, causing an increase in Parkinson ’ s symptoms, such as tremor and difficulty walking. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2017 Category: American Health Source Type: news
FDA approves drug to treat Parkinson ’s disease
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2017 Category: American Health Source Type: news
